HEADER ANTIBIOTIC/PEPTIDE 19-OCT-01 1GO6 TITLE BALHIMYCIN IN COMPLEX WITH LYS-D-ALA-D-ALA COMPND MOL_ID: 1; COMPND 2 MOLECULE: BALHIMYCIN; COMPND 3 CHAIN: A, C, E, G, I, K, M, O; COMPND 4 MOL_ID: 2; COMPND 5 MOLECULE: PEPTIDE LYS-DAL-DAL; COMPND 6 CHAIN: B, D, F, H; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: AMYCOLATOPSIS SP.; SOURCE 3 ORGANISM_TAXID: 37632; SOURCE 4 STRAIN: Y-86, 21022; SOURCE 5 MOL_ID: 2; SOURCE 6 SYNTHETIC: YES; SOURCE 7 ORGANISM_SCIENTIFIC: SYNTHETIC CONSTRUCT; SOURCE 8 ORGANISM_TAXID: 32630 KEYWDS GLYCOPEPTIDE, ANTIBIOTICS, ANTIBIOTIC-PEPTIDE COMPLEX, BACTERIAL KEYWDS 2 CELL-WALL EXPDTA X-RAY DIFFRACTION AUTHOR C.LEHMANN,G.BUNKOCZI,L.VERTESY,G.M.SHELDRICK REVDAT 12 29-JUL-20 1GO6 1 COMPND REMARK HETNAM LINK REVDAT 12 2 1 SITE REVDAT 11 24-JUL-19 1GO6 1 REMARK REVDAT 10 10-JUL-19 1GO6 1 REMARK REVDAT 9 22-MAY-19 1GO6 1 REMARK REVDAT 8 24-APR-19 1GO6 1 REMARK SEQRES LINK REVDAT 7 08-FEB-17 1GO6 1 SOURCE REVDAT 6 20-MAR-13 1GO6 1 REMARK REVDAT 5 27-FEB-13 1GO6 1 REMARK REVDAT 4 25-JUL-12 1GO6 1 HETNAM HETATM ANISOU REVDAT 3 13-JUL-11 1GO6 1 VERSN REVDAT 2 24-FEB-09 1GO6 1 VERSN REVDAT 1 13-JUN-02 1GO6 0 JRNL AUTH C.LEHMANN,G.BUNKOCZI,L.VERTESY,G.M.SHELDRICK JRNL TITL STRUCTURES OF GLYCOPEPTIDE ANTIBIOTICS WITH PEPTIDES THAT JRNL TITL 2 MODEL BACTERIAL CELL-WALL PRECURSORS JRNL REF J.MOL.BIOL. V. 318 723 2002 JRNL REFN ISSN 0022-2836 JRNL PMID 12054818 JRNL DOI 10.1016/S0022-2836(02)00146-8 REMARK 2 REMARK 2 RESOLUTION. 0.98 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 0.98 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 89.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.6 REMARK 3 CROSS-VALIDATION METHOD : FREE R-VALUE REMARK 3 FREE R VALUE TEST SET SELECTION : THIN SHELLS REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : 0.130 REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.129 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.159 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : 3629 REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 72913 REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : 0.125 REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : 0.124 REMARK 3 FREE R VALUE (F>4SIG(F)) : 0.154 REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : 5.000 REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : 3251 REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 65449 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 720 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 246 REMARK 3 SOLVENT ATOMS : 259 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : 1106.6 REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : 728.86 REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : NULL REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : 12104 REMARK 3 NUMBER OF RESTRAINTS : 16491 REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.022 REMARK 3 ANGLE DISTANCES (A) : 0.045 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : NULL REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : 0.096 REMARK 3 ZERO CHIRAL VOLUMES (A**3) : 0.097 REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : 0.076 REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : 0.063 REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : 0.006 REMARK 3 SIMILAR ADP COMPONENTS (A**2) : 0.029 REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : 0.082 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: MOEWS & KRETSINGER REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : ENGH & HUBER REMARK 3 SPECIAL CASE: RESTRAINTS FOR BALHIMYCIN FROM CSD REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 1GO6 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 19-OCT-01. REMARK 100 THE DEPOSITION ID IS D_1290008712. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 15-SEP-98 REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 4.00 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : EMBL/DESY, HAMBURG REMARK 200 BEAMLINE : X11 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9076 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 72913 REMARK 200 RESOLUTION RANGE HIGH (A) : 0.980 REMARK 200 RESOLUTION RANGE LOW (A) : 90.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.6 REMARK 200 DATA REDUNDANCY : 3.500 REMARK 200 R MERGE (I) : 0.04400 REMARK 200 R SYM (I) : NULL REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 14.8100 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 0.98 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.10 REMARK 200 COMPLETENESS FOR SHELL (%) : 95.5 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.17740 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 <I/SIGMA(I)> FOR SHELL : 6.720 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: SAD REMARK 200 SOFTWARE USED: SHELXD REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: ADDITIONAL DATA SET WAS COLLECTED AT CU KALPHA RADIATION REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 57.60 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.90 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.3 M NA3CIT/H3CIT PH=4, 25% MPD, PH REMARK 280 4.00 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X+1/2,Y+1/2,-Z REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 44.46350 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 14.01250 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 44.46350 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 14.01250 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: HEXAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 5490 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 6660 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -42.4 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D, I, K REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1770 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 2110 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -3.3 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: M, O REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TETRAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1430 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 3080 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -9.2 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: E, F, G, H REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 BALHIMYCIN IS A TRICYCLIC GLYCOPEPTIDE. THE SCAFFOLD IS REMARK 400 A HEPTAPEPTIDE WITH THE CONFIGURATION D-D-L-D-D-L-L. IT IS REMARK 400 FURTHER GLYCOSYLATED BY TWO MONOSACCHARIDES: A D-GLUCOSE REMARK 400 AND A 4-OXO-VANCOSAMINE. REMARK 400 HERE, BALHIMYCIN IS REPRESENTED GROUPING TOGETHER THE REMARK 400 SEQUENCE (SEQRES) AND TWO LIGANDS (HET) DVC AND BGC REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: BALHIMYCIN REMARK 400 CHAIN: A, C, E, G, I, K, M, O REMARK 400 COMPONENT_1: PEPTIDE LIKE SEQUENCE RESIDUES 1 TO 7 REMARK 400 COMPONENT_2: SUGAR RESIDUES 8 AND 9 REMARK 400 DESCRIPTION: BALHIMYCIN IS A TRICYCLIC HEPTAPEPTIDE REMARK 400 GLYCOSYLATED BY D-GLUCOSE (RESIDUE 8) ON REMARK 400 RESIDUE 4 AND BY 4-OXO-VANCOSAMINE REMARK 400 (RESIDUE 9) ON RESIDUE 6. REMARK 400 REMARK 400 THE BALHIMYCIN IS GLYCOPEPTIDE, A MEMBER OF ANTIBIOTIC, REMARK 400 ANTIMICROBIAL CLASS. REMARK 400 REMARK 400 GROUP: 1 REMARK 400 NAME: BALHIMYCIN REMARK 400 CHAIN: A, C, E, G, I, K, M, O REMARK 400 COMPONENT_1: PEPTIDE LIKE POLYMER REMARK 400 COMPONENT_2: RESIDUE BGC REMARK 400 COMPONENT_3: RESIDUE DVC REMARK 400 DESCRIPTION: BALHIMYCIN IS A TRICYCLIC HEPTAPEPTIDE GLYCOSYLATED REMARK 400 BY D-GLUCOSE (RESIDUE 8) ON RESIDUE 4 AND BY 4-OXO- REMARK 400 VANCOSAMINE (RESIDUE 9) ON RESIDUE 6. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN G 3 -51.73 -123.27 REMARK 500 ASN O 3 -60.33 -105.61 REMARK 500 REMARK 500 REMARK: NULL REMARK 610 REMARK 610 MISSING HETEROATOM REMARK 610 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 610 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 610 I=INSERTION CODE): REMARK 610 M RES C SSEQI REMARK 610 CIT E 20 REMARK 610 CIT K 20 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1HHY RELATED DB: PDB REMARK 900 CRYSTAL STRUCURE OF DEGLUCOBALHIMYCIN COMPLEXED WITH DAL-DAL REMARK 900 RELATED ID: 1HHU RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF BALHIMYCIN COMPLEXED WITH DAL-DAL REMARK 900 RELATED ID: 1HHZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF DEGLUCOBALHIMYCIN COPMLEXED WITH CELL WALL REMARK 900 PENTAPEPTIDE DBREF 1GO6 A 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1GO6 B 1 3 PDB 1GO6 1GO6 1 3 DBREF 1GO6 C 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1GO6 D 1 3 PDB 1GO6 1GO6 1 3 DBREF 1GO6 E 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1GO6 F 1 3 PDB 1GO6 1GO6 1 3 DBREF 1GO6 G 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1GO6 H 1 3 PDB 1GO6 1GO6 1 3 DBREF 1GO6 I 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1GO6 K 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1GO6 M 1 7 NOR NOR00709 NOR00709 1 7 DBREF 1GO6 O 1 7 NOR NOR00709 NOR00709 1 7 SEQRES 1 A 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 B 3 LYS DAL DAL SEQRES 1 C 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 D 3 LYS DAL DAL SEQRES 1 E 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 F 3 LYS DAL DAL SEQRES 1 G 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 H 3 LYS DAL DAL SEQRES 1 I 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 K 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 M 7 MLU OMZ ASN GHP GHP OMY 3FG SEQRES 1 O 7 MLU OMZ ASN GHP GHP OMY 3FG MODRES 1GO6 OMY A 6 TYR MODRES 1GO6 OMY C 6 TYR MODRES 1GO6 OMY E 6 TYR MODRES 1GO6 OMY G 6 TYR MODRES 1GO6 OMY I 6 TYR MODRES 1GO6 OMY K 6 TYR MODRES 1GO6 OMY M 6 TYR MODRES 1GO6 OMY O 6 TYR HET MLU A 1 9 HET OMZ A 2 14 HET GHP A 4 11 HET GHP A 5 11 HET OMY A 6 14 HET 3FG A 7 13 HET DAL B 2 5 HET DAL B 3 6 HET MLU C 1 9 HET OMZ C 2 14 HET GHP C 4 11 HET GHP C 5 11 HET OMY C 6 14 HET 3FG C 7 13 HET DAL D 2 5 HET DAL D 3 6 HET MLU E 1 12 HET OMZ E 2 14 HET GHP E 4 11 HET GHP E 5 11 HET OMY E 6 14 HET 3FG E 7 13 HET DAL F 2 7 HET DAL F 3 6 HET MLU G 1 9 HET OMZ G 2 14 HET GHP G 4 11 HET GHP G 5 11 HET OMY G 6 16 HET 3FG G 7 13 HET DAL H 2 5 HET DAL H 3 6 HET MLU I 1 18 HET OMZ I 2 16 HET GHP I 4 11 HET GHP I 5 11 HET OMY I 6 14 HET 3FG I 7 13 HET MLU K 1 18 HET OMZ K 2 16 HET GHP K 4 11 HET GHP K 5 11 HET OMY K 6 14 HET 3FG K 7 13 HET MLU M 1 9 HET OMZ M 2 14 HET GHP M 4 12 HET GHP M 5 11 HET OMY M 6 16 HET 3FG M 7 13 HET MLU O 1 18 HET OMZ O 2 16 HET GHP O 4 11 HET GHP O 5 11 HET OMY O 6 16 HET 3FG O 7 13 HET BGC A 8 11 HET DVC A 9 11 HET BGC C 8 11 HET DVC C 9 11 HET BGC E 8 11 HET DVC E 9 11 HET CIT E 20 9 HET BGC G 8 11 HET DVC G 9 22 HET BGC I 8 11 HET DVC I 9 11 HET CIT I 20 13 HET MRD I 21 8 HET BGC K 8 11 HET DVC K 9 11 HET CIT K 20 6 HET MPD K 21 8 HET BGC M 8 22 HET DVC M 9 22 HET CIT M 20 13 HET BGC O 8 14 HET DVC O 9 22 HET CIT O 20 13 HETNAM MLU N-METHYL-D-LEUCINE HETNAM OMZ (BETAR)-3-CHLORO-BETA-HYDROXY-D-TYROSINE HETNAM GHP (2R)-AMINO(4-HYDROXYPHENYL)ETHANOIC ACID HETNAM OMY (BETAR)-3-CHLORO-BETA-HYDROXY-L-TYROSINE HETNAM 3FG (2S)-AMINO(3,5-DIHYDROXYPHENYL)ETHANOIC ACID HETNAM DAL D-ALANINE HETNAM BGC BETA-D-GLUCOPYRANOSE HETNAM DVC (2R,4S,6S)-4-AZANYL-4,6-DIMETHYL-OXANE-2,5,5-TRIOL HETNAM CIT CITRIC ACID HETNAM MRD (4R)-2-METHYLPENTANE-2,4-DIOL HETNAM MPD (4S)-2-METHYL-2,4-PENTANEDIOL FORMUL 1 MLU 8(C7 H15 N O2) FORMUL 1 OMZ 8(C9 H10 CL N O4) FORMUL 1 GHP 16(C8 H9 N O3) FORMUL 1 OMY 8(C9 H10 CL N O4) FORMUL 1 3FG 8(C8 H9 N O4) FORMUL 2 DAL 8(C3 H7 N O2) FORMUL 13 BGC 8(C6 H12 O6) FORMUL 14 DVC 8(C7 H15 N O4) FORMUL 19 CIT 5(C6 H8 O7) FORMUL 25 MRD C6 H14 O2 FORMUL 29 MPD C6 H14 O2 FORMUL 36 HOH *259(H2 O) SHEET 1 AA 2 GHP A 4 GHP A 5 0 SHEET 2 AA 2 DAL B 2 DAL B 3 -1 O DAL B 3 N GHP A 4 SHEET 1 CA 2 GHP C 4 GHP C 5 0 SHEET 2 CA 2 DAL D 2 DAL D 3 -1 O DAL D 3 N GHP C 4 SHEET 1 EA 2 GHP E 4 GHP E 5 0 SHEET 2 EA 2 DAL F 2 DAL F 3 -1 O DAL F 3 N GHP E 4 LINK C MLU A 1 N OMZ A 2 1555 1555 1.35 LINK C OMZ A 2 N ASN A 3 1555 1555 1.32 LINK OH OMZ A 2 C3 GHP A 4 1555 1555 1.37 LINK C ASN A 3 N GHP A 4 1555 1555 1.33 LINK C GHP A 4 N GHP A 5 1555 1555 1.34 LINK C5 GHP A 4 OCZ OMY A 6 1555 1555 1.39 LINK O4 GHP A 4 C1 BGC A 8 1555 1555 1.43 LINK C GHP A 5 N OMY A 6 1555 1555 1.33 LINK C5 GHP A 5 CG1 3FG A 7 1555 1555 1.49 LINK C OMY A 6 N 3FG A 7 1555 1555 1.33 LINK ODE OMY A 6 C1 DVC A 9 1555 1555 1.42 LINK C LYS B 1 N DAL B 2 1555 1555 1.31 LINK C DAL B 2 N DAL B 3 1555 1555 1.33 LINK C MLU C 1 N OMZ C 2 1555 1555 1.33 LINK C OMZ C 2 N ASN C 3 1555 1555 1.31 LINK OH OMZ C 2 C3 GHP C 4 1555 1555 1.39 LINK C ASN C 3 N GHP C 4 1555 1555 1.32 LINK C GHP C 4 N GHP C 5 1555 1555 1.35 LINK C5 GHP C 4 OCZ OMY C 6 1555 1555 1.40 LINK O4 GHP C 4 C1 BGC C 8 1555 1555 1.42 LINK C GHP C 5 N OMY C 6 1555 1555 1.33 LINK C5 GHP C 5 CG1 3FG C 7 1555 1555 1.49 LINK C OMY C 6 N 3FG C 7 1555 1555 1.34 LINK ODE OMY C 6 C1 DVC C 9 1555 1555 1.44 LINK C LYS D 1 N DAL D 2 1555 1555 1.31 LINK C DAL D 2 N DAL D 3 1555 1555 1.32 LINK C MLU E 1 N OMZ E 2 1555 1555 1.35 LINK C OMZ E 2 N ASN E 3 1555 1555 1.33 LINK OH OMZ E 2 C3 GHP E 4 1555 1555 1.38 LINK C ASN E 3 N GHP E 4 1555 1555 1.34 LINK C GHP E 4 N GHP E 5 1555 1555 1.32 LINK C5 GHP E 4 OCZ OMY E 6 1555 1555 1.38 LINK O4 GHP E 4 C1 BGC E 8 1555 1555 1.43 LINK C GHP E 5 N OMY E 6 1555 1555 1.32 LINK C5 GHP E 5 CG1 3FG E 7 1555 1555 1.48 LINK C OMY E 6 N 3FG E 7 1555 1555 1.35 LINK ODE OMY E 6 C1 DVC E 9 1555 1555 1.39 LINK C ALYS F 1 N ADAL F 2 1555 1555 1.29 LINK C BLYS F 1 N BDAL F 2 1555 1555 1.32 LINK C DAL F 2 N DAL F 3 1555 1555 1.32 LINK C MLU G 1 N OMZ G 2 1555 1555 1.35 LINK C OMZ G 2 N ASN G 3 1555 1555 1.33 LINK OH OMZ G 2 C3 GHP G 4 1555 1555 1.39 LINK C ASN G 3 N GHP G 4 1555 1555 1.31 LINK C GHP G 4 N GHP G 5 1555 1555 1.35 LINK C5 GHP G 4 OCZ OMY G 6 1555 1555 1.38 LINK O4 GHP G 4 C1 BGC G 8 1555 1555 1.44 LINK C GHP G 5 N OMY G 6 1555 1555 1.35 LINK C5 GHP G 5 CG1 3FG G 7 1555 1555 1.50 LINK C OMY G 6 N 3FG G 7 1555 1555 1.34 LINK ODEBOMY G 6 C1 BDVC G 9 1555 1555 1.41 LINK ODEAOMY G 6 C1 ADVC G 9 1555 1555 1.41 LINK C LYS H 1 N DAL H 2 1555 1555 1.31 LINK C DAL H 2 N DAL H 3 1555 1555 1.31 LINK C BMLU I 1 N BOMZ I 2 1555 1555 1.36 LINK C AMLU I 1 N AOMZ I 2 1555 1555 1.37 LINK C OMZ I 2 N ASN I 3 1555 1555 1.32 LINK OH OMZ I 2 C3 GHP I 4 1555 1555 1.37 LINK C ASN I 3 N GHP I 4 1555 1555 1.32 LINK C GHP I 4 N GHP I 5 1555 1555 1.34 LINK C5 GHP I 4 OCZ OMY I 6 1555 1555 1.36 LINK O4 GHP I 4 C1 BGC I 8 1555 1555 1.40 LINK C GHP I 5 N OMY I 6 1555 1555 1.34 LINK C5 GHP I 5 CG1 3FG I 7 1555 1555 1.50 LINK C OMY I 6 N 3FG I 7 1555 1555 1.33 LINK ODE OMY I 6 C1 DVC I 9 1555 1555 1.40 LINK C AMLU K 1 N AOMZ K 2 1555 1555 1.39 LINK C BMLU K 1 N BOMZ K 2 1555 1555 1.38 LINK C OMZ K 2 N ASN K 3 1555 1555 1.32 LINK OH OMZ K 2 C3 GHP K 4 1555 1555 1.40 LINK C ASN K 3 N GHP K 4 1555 1555 1.33 LINK C GHP K 4 N GHP K 5 1555 1555 1.31 LINK C5 GHP K 4 OCZ OMY K 6 1555 1555 1.39 LINK O4 GHP K 4 C1 BGC K 8 1555 1555 1.42 LINK C GHP K 5 N OMY K 6 1555 1555 1.31 LINK C5 GHP K 5 CG1 3FG K 7 1555 1555 1.49 LINK C OMY K 6 N 3FG K 7 1555 1555 1.32 LINK ODE OMY K 6 C1 DVC K 9 1555 1555 1.42 LINK C MLU M 1 N OMZ M 2 1555 1555 1.36 LINK C OMZ M 2 N ASN M 3 1555 1555 1.30 LINK OH OMZ M 2 C3 GHP M 4 1555 1555 1.41 LINK C ASN M 3 N GHP M 4 1555 1555 1.31 LINK C GHP M 4 N GHP M 5 1555 1555 1.34 LINK C5 GHP M 4 OCZ OMY M 6 1555 1555 1.37 LINK O4 BGHP M 4 C1 BBGC M 8 1555 1555 1.43 LINK O4 AGHP M 4 C1 ABGC M 8 1555 1555 1.44 LINK C GHP M 5 N OMY M 6 1555 1555 1.33 LINK C5 GHP M 5 CG1 3FG M 7 1555 1555 1.49 LINK C OMY M 6 N 3FG M 7 1555 1555 1.36 LINK ODEBOMY M 6 C1 BDVC M 9 1555 1555 1.41 LINK ODEAOMY M 6 C1 ADVC M 9 1555 1555 1.43 LINK C BMLU O 1 N BOMZ O 2 1555 1555 1.37 LINK C AMLU O 1 N AOMZ O 2 1555 1555 1.37 LINK C OMZ O 2 N ASN O 3 1555 1555 1.29 LINK OH OMZ O 2 C3 GHP O 4 1555 1555 1.36 LINK C ASN O 3 N GHP O 4 1555 1555 1.34 LINK C GHP O 4 N GHP O 5 1555 1555 1.33 LINK C5 GHP O 4 OCZ OMY O 6 1555 1555 1.35 LINK O4 GHP O 4 C1 BGC O 8 1555 1555 1.41 LINK C GHP O 5 N OMY O 6 1555 1555 1.33 LINK C5 GHP O 5 CG1 3FG O 7 1555 1555 1.49 LINK C OMY O 6 N 3FG O 7 1555 1555 1.34 LINK ODEBOMY O 6 C1 BDVC O 9 1555 1555 1.40 LINK ODEAOMY O 6 C1 ADVC O 9 1555 1555 1.41 CISPEP 1 GHP A 5 OMY A 6 0 12.30 CISPEP 2 GHP C 5 OMY C 6 0 9.93 CISPEP 3 GHP E 5 OMY E 6 0 12.37 CISPEP 4 GHP G 5 OMY G 6 0 12.22 CISPEP 5 GHP I 5 OMY I 6 0 7.02 CISPEP 6 GHP K 5 OMY K 6 0 4.91 CISPEP 7 GHP M 5 OMY M 6 0 8.60 CISPEP 8 GHP O 5 OMY O 6 0 10.20 CRYST1 88.927 28.025 50.707 90.00 90.00 90.00 P 21 21 2 32 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.011245 0.000000 0.000000 0.00000 SCALE2 0.000000 0.035682 0.000000 0.00000 SCALE3 0.000000 0.000000 0.019721 0.00000 MTRIX1 1 0.981900 0.189380 0.001160 -1.10154 1 MTRIX2 1 0.189380 -0.981900 0.001730 10.82174 1 MTRIX3 1 0.001460 -0.001480 -1.000000 76.56329 1 MTRIX1 2 -0.735960 0.644860 -0.206170 131.91583 1 MTRIX2 2 -0.676960 -0.696850 0.236910 61.36913 1 MTRIX3 2 0.009100 0.313930 0.949400 7.03697 1 MTRIX1 3 -0.607780 -0.769430 0.196450 124.77338 1 MTRIX2 3 -0.791250 0.565790 -0.231980 71.83916 1 MTRIX3 3 0.067340 -0.296430 -0.952680 83.28141 1 MTRIX1 4 0.073400 0.993390 -0.088290 64.14457 1 MTRIX2 4 0.994910 -0.079070 -0.062490 -61.33841 1 MTRIX3 4 -0.069060 -0.083260 -0.994130 102.40584 1 MTRIX1 5 0.277390 -0.954640 0.108280 66.03882 1 MTRIX2 5 0.955950 0.285500 0.068150 -67.88586 1 MTRIX3 5 -0.095970 0.084610 0.991780 26.25597 1 MTRIX1 6 0.610840 -0.789980 0.052920 63.37468 1 MTRIX2 6 0.783830 0.612810 0.100430 -51.10247 1 MTRIX3 6 -0.111770 -0.019860 0.993540 17.46341 1 MTRIX1 7 0.821230 0.570590 -0.000890 17.46895 1 MTRIX2 7 0.569360 -0.819560 -0.064480 5.25723 1 MTRIX3 7 -0.037520 0.052440 -0.997920 86.46360 1 HETATM 1 N MLU A 1 76.026 20.194 37.310 1.00 10.04 N ANISOU 1 N MLU A 1 1266 1458 1089 156 -47 16 N HETATM 2 CN MLU A 1 77.110 21.197 37.613 1.00 11.46 C ANISOU 2 CN MLU A 1 1300 1433 1621 -45 71 206 C HETATM 3 CA MLU A 1 75.872 19.147 38.377 1.00 8.69 C ANISOU 3 CA MLU A 1 931 1363 1006 120 -52 -22 C HETATM 4 C MLU A 1 75.354 19.864 39.615 1.00 8.94 C ANISOU 4 C MLU A 1 936 1431 1032 140 -14 28 C HETATM 5 O MLU A 1 74.291 20.417 39.587 1.00 10.27 O ANISOU 5 O MLU A 1 994 1775 1134 330 -63 -67 O HETATM 6 CB MLU A 1 74.873 18.097 37.905 1.00 9.46 C ANISOU 6 CB MLU A 1 988 1571 1037 70 -24 -95 C HETATM 7 CG MLU A 1 74.582 16.990 38.932 1.00 9.39 C ANISOU 7 CG MLU A 1 921 1430 1215 35 -65 -108 C HETATM 8 CD1 MLU A 1 75.789 16.130 39.227 1.00 9.79 C ANISOU 8 CD1 MLU A 1 982 1610 1130 -37 -24 52 C HETATM 9 CD2 MLU A 1 73.408 16.161 38.428 1.00 10.76 C ANISOU 9 CD2 MLU A 1 1060 1615 1411 -53 -162 -357 C HETATM 10 N OMZ A 2 76.163 19.845 40.693 1.00 8.34 N ANISOU 10 N OMZ A 2 909 1228 1031 67 -57 -18 N HETATM 11 CA OMZ A 2 75.766 20.536 41.882 1.00 8.63 C ANISOU 11 CA OMZ A 2 918 1284 1077 76 73 24 C HETATM 12 C OMZ A 2 75.679 19.671 43.126 1.00 8.32 C ANISOU 12 C OMZ A 2 939 1239 983 -10 -62 -65 C HETATM 13 O OMZ A 2 75.158 20.137 44.127 1.00 9.30 O ANISOU 13 O OMZ A 2 1142 1314 1077 46 74 -85 O HETATM 14 CB OMZ A 2 76.584 21.858 42.153 1.00 9.24 C ANISOU 14 CB OMZ A 2 1136 1252 1122 51 -53 3 C HETATM 15 OC OMZ A 2 76.619 22.547 40.915 1.00 10.12 O ANISOU 15 OC OMZ A 2 1310 1229 1307 -1 -106 152 O HETATM 16 CG OMZ A 2 77.976 21.596 42.658 1.00 8.73 C ANISOU 16 CG OMZ A 2 1077 1114 1127 -36 -7 50 C HETATM 17 CD1 OMZ A 2 78.197 21.703 44.039 1.00 9.26 C ANISOU 17 CD1 OMZ A 2 1089 1285 1146 -76 41 -52 C HETATM 18 CD2 OMZ A 2 79.032 21.196 41.841 1.00 8.91 C ANISOU 18 CD2 OMZ A 2 1124 1186 1075 -148 11 102 C HETATM 19 CE1 OMZ A 2 79.422 21.381 44.579 1.00 9.51 C ANISOU 19 CE1 OMZ A 2 1020 1390 1205 -119 9 67 C HETATM 20 CL OMZ A 2 79.713 21.519 46.244 1.00 14.13 CL ANISOU 20 CL OMZ A 2 1676 2151 1543 -152 -47 -71 CL HETATM 21 CE2 OMZ A 2 80.254 20.851 42.357 1.00 9.39 C ANISOU 21 CE2 OMZ A 2 1054 1281 1235 -53 -11 -35 C HETATM 22 CZ OMZ A 2 80.433 20.910 43.749 1.00 9.12 C ANISOU 22 CZ OMZ A 2 957 1329 1178 -112 -55 112 C HETATM 23 OH OMZ A 2 81.644 20.444 44.285 1.00 9.31 O ANISOU 23 OH OMZ A 2 935 1358 1245 -133 -52 125 O